Growth, Allergy and Neurodevelopment in Infants on Hydrolysed Formula

Infant Formula Clinical Trial

— GRANDIOSA  

Official title:

GRANDIOSA - Growth, Allergy and Neurodevelopment in Infants on Hydrolysed Formula

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05578716
• Other study ID #: 20210707401
• Status: Recruiting
• Phase: N/A
• Start date: October 3, 2022
• Est. completion date: June 2026

Study information

• Verified date: December 2023
• Source: Umeå University
• Contact: Magnus Domellöf, MD, PhD
• Phone: +46907852128
• Email: magnus.domellof[@]umu.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Breastfeeding is the recommended diet for all infants during the first half of infancy and is associated with numerous health benefits. However, when breastfeeding is not possible, an infant formula is the only nutritive alternative. Formula-fed infants have a different growth pattern compared to breastfed infants. Studies have shown that the higher protein content in infant formula compared to breastmilk results in a more rapid weight gain and an increased risk of overweight and obesity in childhood. For this reason, both quantity and quality of protein in infant formulae have been optimized during the last decade, to better meet the needs of infants and to support growth close to that of breastfed infants. Protein hydrolysis, a common modification of infant formulae, has originally been developed for treatment of cow's milk protein allergy. Certain hydrolysed formulae have been suggested to prevent atopic eczema when given to infants with a family history of allergic disease but as of yet, the allergy preventive effect in infants without increased risk of allergic disease has been little studied. Partially hydrolysed infant formulae have also been suggested to reduce common functional gastrointestinal symptoms in infants. New protein hydrolysates are continually developed for use in infant formulae, with the aim of reducing allergenicity, while ensuring optimal growth and development of infants. It is important to study the effects on growth and health outcomes in infants who are fed formulae based on these newly developed hydrolysates as compared to those fed standard intact protein formulae or breastmilk. The overall aims of the current study are to evaluate the effects of two new hydrolysates on growth, immunological biomarkers, neurodevelopment, protein metabolism and gut microbiota in a randomized, controlled clinical trial of healthy infants. In compliance with European Food Safety Authority (EFSA) regulations for novel infant formulas based on hydrolysed protein, the primary outcome is change in weight standard deviation score (SDS) from baseline until 5 months of age.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 312
• Est. completion date: June 2026
• Est. primary completion date: June 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 4 Weeks to 8 Weeks

Eligibility

Inclusion Criteria:

• Healthy infants born at term
• Birth weight 2500 to 4500 gram
• Either exclusive breast-feeding (reference group) or exclusive formula-feeding (intervention and control group)

Exclusion Criteria:

• Suspected or verified food allergy
• Suspected or verified infant colic

Related Conditions & MeSH terms

• Hypersensitivity
• Infant Formula

Intervention

Dietary Supplement:
• Partially hydrolysed formula
Partially hydrolysed formula

Locations

Country	Name	City	State
Sweden	Department of clinical science, Preventive Paediatrics, Lund university	Malmö
Sweden	Department of Clinical Sciences, Pediatrics, Umeå University Hospital	Umeå

Sponsors (3)

Lead Sponsor	Collaborator
Umeå University	Arla Foods, Lund University

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weight	Primary outcome is weight Standard Deviation Score (SDS) at the end of the intervention.	At 5 months of age
Secondary	Length.	Growth pattern during the course of the intervention measured by length in centimeters and SDS.	At enrollment at 2 months of age and monthly during the intervention up to 5 months of age.
Secondary	Head circumference.	Growth pattern during the course of the intervention measured by head circumference in centimeters and SDS.	At enrollment at 2 months of age and monthly during the intervention up to 5 months of age.
Secondary	Body composition	Assessing differences in body composition between study groups using fat percentage as measured by PeaPod (Pletysmography).	At 4 months of age
Secondary	Gastrointestinal tolerance.	Gastrointestinal tolerance using diary for information about stool frequency and consistency (in four grades from diarrhea to hard stools) in combination with questionnaire filled in by the parents based on Rome IV criteria for functional gastrointestinal disorders.	At enrollment at 2 months of age and during the intervention up to 5 months of age.
Secondary	Gastrointestinal immunology.	Markers of gastrointestinal immune activation using analysis of calprotectin, eosinophilic derived neurotoxin and secretory Immunoglobulin A (IgA) in fecal samples.	At enrollment at 2 months of age and during the intervention up to 5 months of age.
Secondary	Eczema severity, parent report.	Parents will fill in the Patient-Oriented Eczema Measure (POEM) score monthly during the intervention.	At enrollment at 2 months of age and during the intervention up to 5 months of age.
Secondary	Eczema severity, clinical assessment.	Excema severity is assessed at every study visit using the Eczema Area and Severity Index (EASI).	At enrollment at 2 months of age and during the intervention up to 5 months of age.
Secondary	Allergy.	Sensitization to cow's milk protein is assessed by Immunoglobulin E (IgE) in serum using ImmunoCap.	At enrollment at 2 months of age and at the end of the intervention at 5 months of age.
Secondary	Immunologic activity.	Blood cytokine patterns using Luminex: Interleukin 2 (IL-2) as a marker of general T cell activity. Interferon gamma (IFN-?) as a marker of Helper T cells type 1 (Th1) activity. Interleukin 4 (IL-4) as a marker of helper T cells type 2 (Th2) activity. Tumor growth factor beta type 1 (TGF-ß1) as a marker of T cell regulatory activity. Interleukin 17 A (IL17-A) as a marker of helper T cell type 17 (Th17) activity. C reactive protein (CRP) in plasma as a marker of general inflammatory response.	At enrollment at 2 months of age and at the end of the intervention at 5 months of age.
Secondary	Metabolic biomarkers in blood.	Insulin-like growth factor-1 (IGF-1). Insulin. C-peptide. Leptin. Leptin-receptor.	At enrollment at 2 months of age and at the end of the intervention at 5 months of age.
Secondary	Markers of protein metabolism.	Plasma amino acids. Blood urea nitrogen.	At enrollment at 2 months of age and at the end of the intervention at 5 months of age.
Secondary	Microbiota	Composition and diversity of the gut microbiota analysed in fecal samples. Bacterial DNA will be extracted and the V3-V4 region of the 16S rRNA gene will be amplified. Sequencing of all samples takes place on the Illumina MiSeq platform. Based on the results, we will also use metagenomic or Nanopore sequencing for deeper characterization of microbial composition and functions.	At enrollment at 2 months of age and during the intervention up to 5 months of age.
Secondary	Neurodevelopment at 6 months of age.	Response in cerebral blood flow to visual and auditory stimuli as measured by functional near-infrared spectroscopy (fNIRS).	At 6 months of age.
Secondary	Neurodevelopment at 12 months of age.	Bayely scales of infant development (BSID) 3rd edition. Higher score is interpreted as better outcome.	At 12 months of age.
Secondary	Neurodevelopment at 3 years of age.	Wechsler Preschool and Primary Scale of Intelligence (WIPPSI) 4th edition. Higher score is interpreted as better outcome.	At 3 years of age